Results 101 to 110 of about 55,752 (265)

Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5‐Year Real‐Life Experience With Dupilumab

International Journal of Dermatology, EarlyView.
ABSTRACT Background Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has proven to be effective for moderate‐to‐severe AD, but long‐term real‐world data remain limited.
Francesco Leo, Luca Mastorino, Luca Cangialosi, Davide Favre, Chiara Anna Fiasconaro, Yingying Liao, Federico Goso, Niccolò Siliquini, Giovanni Cavaliere, Pietro Quaglino, Simone Ribero, Michela Ortoncelli   +11 more
wiley   +1 more source

A 50‐year‐old man with a 12‐year history of extensive pachymeningeal thickening

Brain Pathology, EarlyView.
Alyssa M. Lee, Siddhartha Gaddamanugu, Kathyrn L. Eschbacher, Aishwarya Ravindran   +3 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68‐week randomized Phase 3 trial

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This open‐label study is a continuation of the 16‐week double‐blind, Phase 3 trial assessing the efficacy and safety of brodalumab 210 mg subcutaneously, till a 68‐week extension period. Continued improvement was seen in the PPPASI 50/75/90 responses, PPPSI scores, PGA 0/1 responses and DLQI. Abstract Background The efficacy and safety of brodalumab in
Masamoto Murakami, Yukari Okubo, Satomi Kobayashi, Natsuko Kikuta, Yoshiumi Ouchi, Kenta Shishido, Tadashi Terui   +6 more
wiley   +1 more source

Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
In this interim analysis of the OLYMPIA long‐term extension trial, nemolizumab exhibited sustained efficacy and was well tolerated through 100 weeks, with most adverse events being mild/moderate. Patients showed clinically meaningful improvements in core signs and symptoms.
Franz J. Legat, Shawn G. Kwatra, Adam Reich, Serge Boulinguez, Athanasios Tsianakas, Maxwell Sauder, Sebastien Barbarot, Jacek C. Szepietowski, Curdin Conrad, Andrew E. Pink, Elke Weisshaar, Laurent Misery, Martin Metz, Vivian T. Laquer, Raja K. Sivamani, Gil Yosipovitch, Diamant Thaçi, Lone Skov, Xiaoxiao Chen, Aliene Noda, Zarif K. Jabbar‐Lopez, Christophe Piketty, Sonja Ständer   +22 more
wiley   +1 more source

For optimal treatment of musculoskeletal pain among elderly individuals, clarification of its aetiology is essential [PDF]

Malaysian Family Physician
Josef Finsterer
doaj   +1 more source

Dupilumab treatment in children aged 6 months to 5 years with severe atopic dermatitis

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The results of this French Early Access Program were consistent with those reported in dupilumab randomized clinical trials in children aged 6 months–5 years with moderate‐to‐severe AD. This research offers insights into the practical use of dupilumab in routine clinical practice.
Audrey Lasek, Nathalia Bellon, Stéphanie Mallet, Hélène Aubert, Carine Vera, Lamia Achour, Claire Thénié, Randy Prescilla, Claire Abasq‐Thomas, Sébastien Barbarot   +9 more
wiley   +1 more source

Is the temporomandibular joint affected by rheumatoid arthritis? A comparative investigation with knee arthritis in an experimental rat model

Journal of Anatomy, EarlyView.
Animals were sensitized with mBSA emulsified in CFA/IFA and subsequently received three intra‐articular injections of mBSA into either the TMJ or the knee (once per week). Mechanical hyperalgesia was assessed using electronic von Frey testing after arthritis establishment at 24 h or 7 days following the third intra‐articular injection.
Ana Carolina de Figueiredo Costa, Luane Macedo de Sousa, Delane Viana Gondim   +2 more
wiley   +1 more source

Psychological Features Associated With Awake Bruxism in Painful TMD: The Role of Anxiety

Journal of Oral Rehabilitation, EarlyView.
Objective: Evaluate the role of anxiety by comparing the frequency of AB behaviours, as well as levels of perceived stress, pain catastrophizing and depressive symptoms among patients with painful TMD, categorised by clinical anxiety levels. Methods and Study Protocol: TMD anxiety subgroups (N = 72): Clinical elevated anxiety symptoms (T ≥ 61) n = 30 ...
Dyanne Medina Flores, Samilla Pontes Braga, Giancarlo De La Torre Canales, Juliana Stuginski‐Barbosa, Paulo César Rodrigues Conti   +4 more
wiley   +1 more source

Modified Dixon MRI to detect subclinical inflammation in clinically suspect arthralgia as a risk factor for rheumatoid arthritis development: should we image one or two hands? [PDF]

RMD Open
van der Kaaij D, Claassen S, van Steenbergen HW, Oei EHG, de Jong PHP, Reijnierse M, van der Helm-van Mil AHM.   +6 more
europepmc   +1 more source